Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

ct, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon).   If not effectively treated, it may result in the need for surgery and hospitalization. Crohn's disease has been estimated to affect as many as half a million Americans.  People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives.

About Cimzia

Certolizumab pegol is the only PEGylated anti-TNF (Tumor Necrosis Factor).  It has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.  Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation.  This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.  The U.S. Food and Drug Administration (FDA) has approved certolizumab pegol for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy.  It is also approved for the treatment of adults with moderately to severely active rheumatoid arthritis.  Certolizumab pegol was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded adequately to conventional treatment in September 2007.

Please visit www.cimzia.com for full prescribing information for CIMZIA®.

Important Safety Information

Risk of Serious Infections and Malignancy

Patients treated with CIMZIA are at an increased risk for developing serious infections that may lead to hospitalization or death.  Most patients who developed these infections we
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.C. , Jan. 23, 2015 For the pharmaceutical ... in dealing with payers. Likewise, the importance of the managed ... will only continue to grow as payer formularies and provider ... therapies. At the same time, managed markets leaders ...
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) ... Market (Indwelling or Foley Catheters, Intermittent Catheters and Male ... Share, Growth, Trends and Forecast 2014 - 2020" ... present, the global market for urinary catheters is experiencing ...
(Date:1/23/2015)...  MedScope ( www.medscope.org ), the leading provider of medical ... Connected World magazine Connected World Award for its ... be used anywhere, anytime. The nomination was made by ... nominating MedScope, Landon Garner , Director of Marketing ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2
... WEST BEND, Wis., Aug. 8, 2011 Eurofins ... service provider and Spaulding Clinical Research, LLC., US-based, ... Device Manufacturer, announce a joint partnership agreement.  This ... facilitates collaboration on integrated clinical services to engage ...
... Va., Aug. 8, 2011 Science Applications International ... has completed the acquisition of Vitalize Consulting Solutions ... and information technology (IT) services for healthcare enterprises. ... the commercial hospital market that are implementing electronic ...
Cached Medicine Technology:Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research 2SAIC Completes Acquisition of Vitalize Consulting Solutions, Inc. 2
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Nashville, TN (PRWEB) January 22, 2015 Gabe’s Chemo ... Chemo Duck App, the first app ever created for kids with ... all Apple phones and devices, is filled with enjoyable games to ... life and treatments. The free app helps to keep kids entertained, ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... ... ... ... ...
... ... ... , ... , , , , ...
... ... ... , ... , , ...
... 2010 winners of the Young Investigator Award. This ... individuals within 5 years of receiving doctoral degrees who ... Biology 2010 meeting in Anaheim in April 2010. ... by a committee on the basis of originality and importance ...
... ... of the Center for Quality Growth and Regional Development at Georgia Institute of Technology, ... Forum: Livability and Sustainable Communities – Taking Action for a Clean Energy Future. ... Atlanta, Ga. (PRWEB) ...
... ... ... ... ...
Cached Medicine News:Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 2Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 3Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 4Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 5Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 6Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 2Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 3Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 4Health News:89 Women Celebrate Mardi Gras with Mammograms 2Health News:89 Women Celebrate Mardi Gras with Mammograms 3Health News:SEBM Young Investigator Awards for 2010 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 2Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 4Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 5Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 6Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 7
... H. pylori Rapid Test Strip and Device ... detection of antibodies to Helicobacter pylori (H. ... to aid in the diagnosis of H. ... age and older. They are intended for ...
Immunoassay for rapid, qualitative detection of IgG antibodies specific to Helicobacter pylori in whole blood....
Clearview H. pylori II uses rapid, two-step technology for the direct detection of H. pylori antibodies. , ,The patented, innovative technology used by Clearview H. pylori II provides highly sen...
... Uni-Gold™ H. pylori assay is intended ... detection of IgG antibodies to Helicobacter ... serum, plasma or whole blood as ... H. pylori infection in patients with ...
Medicine Products: